Food Functionality Research Division, Korea Food Research Institute, Wanju-gun, Republic of Korea.
Department of Pharmacology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Front Endocrinol (Lausanne). 2023 Aug 29;14:1224636. doi: 10.3389/fendo.2023.1224636. eCollection 2023.
The status of an impaired gut microbial community, known as dysbiosis, is associated with metabolic diseases such as obesity and insulin resistance. The use of probiotics has been considered an effective approach for the treatment and prevention of obesity and related gut microbial dysbiosis. The anti-obesity effect of AO356 was recently reported. However, the effect of AO356 on the gut microbiota has not yet been identified. This study aimed to elucidate the effect of AO356 on gut microbiota and ensure its safety for use as a probiotic.
Oral administration of AO356 (10 colony-forming units [CFU]/mg per day, 5 days a week, for 10 weeks) to mice fed a high-fat diet significantly suppressed weight gain and fat mass. We investigated the composition of gut microbiota and explored its association with obesity-related markers.
Oral administration of AO356 significantly changed the gut microbiota and modified the relative abundance of , . were significantly related to the lipid metabolism pathway and obesity-related markers. We also confirmed the safety of AO356 using antibiotics resistance, hemolysis activity, bile salt hydrolase activity, lactate production, and toxicity tests following the safety assessment guidelines of the Ministry of Food and Drug Safety (MFDS).
This study demonstrated that AO356 is not only associated with an anti-obesity effect but also with changes in the gut microbiota and metabolic pathways related to obesity. Furthermore, the overall safety assessment seen in this study could increase the potential use of new probiotic materials with anti-obesity effects.
肠道微生物群落失调（dysbiosis）与肥胖和胰岛素抵抗等代谢疾病有关。使用益生菌被认为是治疗和预防肥胖和相关肠道微生物失调的有效方法。AO356 的抗肥胖作用最近已经被报道。然而，AO356 对肠道微生物群的影响尚未确定。本研究旨在阐明 AO356 对肠道微生物群的影响，并确保其作为益生菌使用的安全性。
给喂食高脂肪饮食的小鼠口服 AO356（每天 10 个菌落形成单位[CFU]/mg，每周 5 天，共 10 周），显著抑制了体重增加和脂肪量。我们研究了肠道微生物群的组成，并探讨了其与肥胖相关标志物的关系。
AO356 的口服给药显著改变了肠道微生物群，并改变了 、 、 的相对丰度。 与脂质代谢途径和肥胖相关标志物显著相关。我们还按照食品药品安全部（MFDS）的安全性评估指南，使用抗生素耐药性、溶血活性、胆盐水解酶活性、乳酸生成和毒性测试，确认了 AO356 的安全性。
本研究表明，AO356 不仅与抗肥胖作用有关，而且与肥胖相关的肠道微生物群和代谢途径的变化有关。此外，本研究中的总体安全性评估可能会增加具有抗肥胖作用的新型益生菌材料的潜在用途。
